Objective The ambulatory blood pressure (ABP) monitoring substudy of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was carried out in a subset of patients from USA, Italy and Denmark. ABP was measured after 1 year in the trial, with the aim of evaluating comparability of ABP levels on valsartan (VAL) and amlodipine (AML)-based regimens.
Introduction
The VALUE (Valsartan Antihypertensive Longterm Use Evaluation) randomized trial was carried out to test the hypothesis that for the same blood pressure (BP) control, a valsartan (VAL)-based regimen would reduce cardiac morbidity and mortality more than treatment based on amlodipine (AML) in hypertensive patients at high cardiovascular risk [1] . No difference in the main outcome was found despite a pronounced difference in achieved office blood pressure in favour of amlodipine, especially in the early months of the study.
The present ambulatory blood pressure monitoring (ABPM) substudy was performed to investigate whether similar office BP levels in the two treatment groups corresponded to similar levels during the entire 24-h period. ABPM was carried out after 1 year of treatment where full titration was supposed to have been carried out -and most patients expected to be maintained on trial medication. Results from previous trials have indicated that significant differences between office BP and ABPM may certainly have an impact on the interpretation of the results obtained [2] . Furthermore we wanted to investigate the effect on heart rates and assess the correlation between achieved ambulatory blood pressure (ABP) levels and the occurrence of cardiovascular endpoints.
Methods

Study design and equipment
The present population originated from the VALUE main study, which enrolled 15 245 hypertensive patients at high coronary risk in 31 countries [3] . Mean follow-up time was 4.2 years and the chosen primary endpoint was the composite of exclusively cardiac morbid and mortal events. Only 7% of the patients were previously untreated, so the great majority were rolled directly over from various treatment regimens to follow a relatively cautious titration schedule, with the initial 2 months on blinded monotherapy and subsequent possibilities of adding first hydrochlorothiazide in increasing doses and later other antihypertensive drugs, attempting to achieve a target office BP at trough of less than 140/90 mmHg. Study medication was administered as a single morning dose.
Three countries (USA, Italy and Denmark), primarily considered representative for the entire patient population, were selected for the ABPM substudy. A total of 47 centres agreed to participate. The study was approved by institutional review committees and all patients gave informed consent. The ABPM procedure was scheduled for the 24-h period prior to the 1-year visit. If this was not possible, a 6-month window on either side of the 1-year visit was allowed. Patients were considered eligible whether they were still taking trial medication at that point or not. Excluded from participation were patients on nightshifts, patients with atrial fibrillation, patients with arm circumference > 42 cm and patients who, at the time of inclusion, were beyond the 1 year visit.
The equipment employed was the Spacelabs 90202 or 90207 oscillometric device supplied by Medifacts Ltd (Maryland, USA and Kö ln, Germany). Depending on arm circumference, two standard cuff sizes were used with application to the non-dominant arm. The patient arrived at the outpatient clinic in the morning between 0700 and 0900 h, not having taken that day's dose of study medication or any other antihypertensive medication. Accordance with simultaneous office mercury sphygmomanometer readings in the sitting position was ensured. The morning dose of the study medication was then administered by the investigator, and the time was recorded. The ABPM device was programmed to inflate every 20 min for the following 25-h monitoring period.
Deflation was programmed at a rate of 8 mmHg per two heart beats. On the day of removal of the equipment, the morning dose of medicine was not given until removal had taken place. The obtained data, which were blinded to the investigator, were transmitted without delay (transtelephonically via computer and modem) to Medifacts Ltd for quality control. This procedure should ensure that 70% successful readings with ! 50 valid readings and a minimum of two valid readings per hour, with the exception of no more than two non-consecutive hours with fewer than two valid readings, had been obtained. If quality criteria were not met, one repeat measurement was allowed during the ensuing 1-2-month period.
Statistical methods
The primary efficacy variable chosen was 24-h mean ambulatory diastolic blood pressure (DBP). Sample size calculation was done on the basis of the test for equivalence, with 90% power for two-sided tests at the 2.5% significance level. An equivalence margin of AE 3 mmHg for the ambulatory DBP was planned.
Based on a previous valsartan study, a standard deviation of 9 mmHg for this parameter was assumed. On this basis a minimum of 470 completed patients was necessary and, with an anticipated drop-out rate of 15%, a total of 554 patients were targeted. Analysis was performed for the intention-to-treat (ITT) population as well as for the per-protocol (PP) population and the on-trial-treatment (OTT) population.
Secondary efficacy variables were mean 24-h systolic blood pressure (SBP) and heart rate (HR).
Hourly means were calculated and separate analyses were carried out for daytime (> 0600 to 2200 h) and nighttime (> 2200 to 0600 h). The analysis of mean ABP over 24 h was performed using a two-way analysis of variance (ANOVA) model with treatment and trial centre as factors.
Split-plot analysis of daytime and night-time mean ABP was performed. The correlation between the level of ABP and cardiovascular mortality and morbidity endpoints was assessed by categorizing mean DBP and the numbers of endpoints in each category. Cox regression with treatment as a factor and a continuous ABPM as a covariate was performed. Significance levels were set at P < 0.05.
Results
At the participating sites 1246 patients were randomized in the main study. Patients alive after 12 months were assessed for eligibility in the ABPM study if no exclusion criteria were present. Of these, a total of 798 fulfilled inclusion criteria and consented to participate. At the end, 659 patients (330 in VAL and 327 in AML) were available for ITT analysis and 625 had a successfully performed ABPM (15 had a re-test). A total of 630 patients could be analysed on an OTT basis and 603 on a PP basis.
The baseline demographic characteristics are given in Table 1 and the qualifying risk and disease factors in Table 2 . At baseline a highly significant difference in the presence of ECG-verified left ventricular hypertrophy (LVH) was found (VAL, 15.7%; AML, 8.0%; P ¼ 002), which was not representative for the findings in the main study (VAL, 12.5%; AML, 11.9%; NS) (data on file, NOVARTIS). Otherwise there were no notable differences between baseline characteristics between patients in the substudy and patients in the main study.
Mean sitting office BP at 12 months was 140.0/ 80.8 mmHg on VAL and 139.6/80.3 mmHg on AML (NS). In the main study a more pronounced difference of 2.0/1.5 mmHg in favour of AML was found at the 12-month visit [1] . Mean sitting office HR was 70.8 bpm on VAL and 71.7 bpm on AML (NS).
The mean daily dose of trial medication was 131.3 mg in VAL and 7.8 mg in AML (at the end of the main study: VAL, 151.7 mg, AML, 8.5 mg). More patients in the AML group were on monotherapy (42.5%) than in the VAL group (33.7%). The same pattern was noticed in the main study, although the figures were lower at the end of the 4.2-year period (AML, 35.3%; VAL, 27.0%). In the ABP substudy the addition of a beta-blocker to therapy was not statistically different in the two groups (VAL, 100 patients, 30.1%; AML, 93 patients, 28.4%). Table 3 gives the ABP and heart rate mean values during the 24-h period by the clock and the calculated means during daytime and night-time. The primary analysis of equivalence in DBP was met. Figure 1 shows the mean ABP and heart rate differences between treatment groups by time after dose. No significant differences between the groups in ABP were present, but HR was significantly higher throughout a major part of the 24-h period in the AML group. In Figs 1a and 1b the hourly differences in SBP and DBP are shown according to the time of dosing. The curves clearly demonstrate a more pronounced effect of the VAL-based regimen on ABP in the first 7 h post dose. However, during the period 20-24 h after dosing, ambulatory SBP levels were significantly lower in the AML group (difference -2.7 mmHg, P ¼ 0.030).
The differences between the office BP and the mean 24-h ABP were of the same magnitude in the two treatment groups(VAL:À6.4/À5.4 mmHg;AML:À6.6/À4.2 mmHg). Acceptable systolic ABP control (< 135 mmHg was achieved in 61.1% of the VAL group and in 61.2% of the AML group. The corresponding figures for diastolic ABP < 85 mmHg were VAL 87.9% and AML 89.6%.
Neither in the ITT nor in the PP population were there any significant differences between treatment groups in respect to BP dipping during the night-time (systolic non-dipping: VAL 62%, AML 67%; diastolic nondipping: VAL 37%, AML 41%).
No influence of gender on the response in ABP could be detected but a higher HR during the entire 24-h period in men than in women was seen on AML (difference: men, þ2.5 bpm versus women, þ0.7 bpm; P < 0.02). Patients with LVH showed no significantly different BP levels in the two treatment arms. Patients with diabetes at baseline had lower ABP and HR values on AML (132.9/73.1 mmHg; 74.8 bpm) than on VAL (135.8/75.2 mmHg; 75.6 bpm). In contrast, a strong tendency in the opposite direction -most pronounced for HR -was noted in patients without diabetes. Diastolic ABP and HR were higher in smokers than in non-smokers but apparently not differently affected by the type of therapy.
The total number of combined cardiovascular endpoints recorded for the entire duration of the trial in the ABPM patients was 80 (VAL, 39; AML, 41). Correlation analysis substantiated a significant relationship between the ABP levels achieved in the whole cohort and the number of cardiac, as well as combined cardiovascular, endpoints (Tables 4 and 5 ). In this respect, night-time ABP appeared to have a superior predictive power compared with daytime ABP, and systolic pressures were more closely related than diastolic to endpoints.
When OTT and PP populations were considered, the results were similar to those of the ITT population. Furthermore, systolic office BP was significantly correlated with hard endpoints although less pronounced than daytime ABP.
Discussion
The present study evaluated the 24-h regulation of ABP in a relatively large sample considered representative of the VALUE population after 12 months in the trial. No ABP baseline data were recorded, but this could be considered less important as the vast majority of the patients were rolled directly over from previous different antihypertensive medications [1] . The important differences in office BP levels in favour of amlodipine found in the main study -where office BP was measured at trough -could neither be confirmed to be present in office BP or during 24-h monitoring in the present cohort. The small difference in mean ABP of about 1 mmHg systolic was Calculated with treatment in model in intention-to-treat (ITT) population. DBP, diastolic blood pressure; SBP, systolic blood pressure. Table 5 Effect of an increase of 10 mmHg in mean ambulatory blood pressure (ABP) and office blood pressure (BP) on cardiac mortality and morbidity or stroke, expressed as hazard ratio (95% confidence interval) Calculated with treatment in model in intention-to-treat (ITT) population. DBP, diastolic blood pressure; SBP, systolic blood pressure. counterbalanced by a diastolic difference of 0.4 mmHg going in the opposite direction.
Nevertheless the analysis of the ABP curves after dosing may possibly partly explain the BP findings in the main study. A different effect on BP in the first hours after dosing and an opposite effect during the last 4 h of the dosing interval was demonstrated -enough to explain the equivalence of mean SPB levels in the two groups, and also suggesting an explanation for the difference in favour of amlodipine in office BP measured 24-25 h after dosing in the main study. In a comparative study with valsartan and amlodipine in elderly patients with isolated systolic hypertension, Palatini et al. [4] also noted a greater antihypertensive effect of valsartan in daytime, with a trough/peak ratio of 0.56 versus 0.77 on amlodipine [4] . A similar comparative study by Eguchi et al. [5] also showed that amlodipine flattened the morning rise in ABP more than valsartan. The differences in BP in the main study were most pronounced during the first 6 months of therapy -in retrospect possibly due to a relatively slow titration scheme and probably also to the choice of a too low maximum dose of valsartan, which did not offer equal initial conditions in the two treatment arms [1] .
The doses of the trial drugs in the present substudy were somewhat smaller than those reported at the end of the main study, but on a percentage basis not different between groups [6] . However, it should be noted that an initiative for better BP control was performed after 1 year, when it was noted that control at that point was not significantly improved compared with the levels after 6 months [6] .
The uneven randomization in the present subset, with patients with LVH without strain being more prevalent in the VAL arm is odd, but probably just a chance finding. The ABP levels in the two groups did not suggest an influence of this difference, even if it could be suspected that such patients would show greater resistance to therapy.
An intriguing finding is the consistent highly significant difference in HR at about 2 bpm during the entire 24-h period. Differences in the use of beta-blockers in the two groups could not explain this finding. Similar results were reported earlier in the study of Palatini et al. [4] . This strongly suggests a difference in sympathetic/parasympathetic activation in favour of valsartan. A significant increment in sympathetic tone has previously been demonstrated for several calcium-channel blockers of the 1,4-dihydropyridine type, and also for amlodipine despite its very smooth antihypertensive action [7] . Recent data comparing the angiotensin-receptor blocker (ARB) telmisartan with amlodipine have indicated that amlodipine causes sympathetic activation during the day and a decrease in parasympathetic activity during the night; whereas telmisartan causes an increase in parasympathetic activity during both night and day [8] . We have found similar results in a small Holter substudy in the VALUE trial [9] . Such differences in treatment effect could possibly be of prognostic significance, especially regarding development of heart failure as a response to long-term excess sympathetic stimulation. In the main VALUE study, a higher incidence of heart failure was found on AML but this did not reach statistical significance (P ¼ 0.12) [1] . It is conceivable that such differences might become clearer with longer observation than the 4.2-year period in VALUE.
The role of a nightly dip in BP for prognosis and the pathophysiological background has been disputed [10] . Most studies in untreated hypertensive patients seem to suggest an impaired prognosis related to the non-dipping status, and the Ohasama study even pointed to this in a population that included 31% treated hypertensives [11] .
In the present study, the prevalence of non-dipping appears to be relatively high in both treatment groups, which of course may reflect the fact that these patients were chosen for a high incidence of disease and risk factors. Little is known about the significance of such a finding in treated hypertensives, but it should be remembered that pharmacokinetic and pharmacodynamic features of the drugs administered will have a deep impact on diurnal BP variation. Thus Hermida et al. [12] showed that moving administration time of valsartan from morning to bedtime resulted in a 73% relative reduction in non-dipper patients. Based on the present results with an evident difference in ABP at the end of the dosing interval, it may be speculated that administration of valsartan in the dosage range used in VALUE would be more rational as a dose at bedtime -or that a daily target dose of 320 mg valsartan would be more appropriate. This might offer better organ protection in the first morning hours, when there is a welldocumented excess of morbid events.
A strong direct association between treated ABP levels and endpoints, as found in the present study, has not been reported in previous clinical controlled trials, even if some of these also evaluated the role of ABPM during treatment [13, 14] . The findings in the present study of a stronger relationship between systolic than diastolic ABP levels and endpoints is in accordance with previous epidemiological observations [15, 16] . Furthermore, the suggestion that night ABP levels are more closely related to endpoints than daytime ABP finds support from findings of previous observations [13, 16, 17] . 
